These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12014969)

  • 1. Stabilization of the helical structure of Y2-selective analogues of neuropeptide Y by lactam bridges.
    Yao S; Smith-White MA; Potter EK; Norton RS
    J Med Chem; 2002 May; 45(11):2310-8. PubMed ID: 12014969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptor.
    Rist B; Zerbe O; Ingenhoven N; Scapozza L; Peers C; Vaughan PF; McDonald RL; Wieland HA; Beck-Sickinger AG
    FEBS Lett; 1996 Sep; 394(2):169-73. PubMed ID: 8843157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPY Y2 receptor agonist, N-acetyl [Leu28,Leu31]NPY24-36, reduces renal vasoconstrictor activity in anaesthetised dogs.
    Mahns DA; Kelly C; McCloskey DI; Potter EK
    J Auton Nerv Syst; 1999 Oct; 78(1):10-7. PubMed ID: 10589818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helical structure and self-association in a 13 residue neuropeptide Y Y2 receptor agonist: relationship to biological activity.
    Barnham KJ; Catalfamo F; Pallaghy PK; Howlett GJ; Norton RS
    Biochim Biophys Acta; 1999 Nov; 1435(1-2):127-37. PubMed ID: 10561544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel neuropeptide Y analog, N-acetyl [Leu28,Leu31]neuropeptide Y-(24-36), with functional specificity for the presynaptic (Y2) receptor.
    Potter EK; Barden JA; McCloskey MJ; Selbie LA; Tseng A; Herzog H; Shine J
    Eur J Pharmacol; 1994 May; 267(3):253-62. PubMed ID: 8088364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.
    Kirby DA; Koerber SC; Craig AG; Feinstein RD; Delmas L; Brown MR; Rivier JE
    J Med Chem; 1993 Feb; 36(3):385-93. PubMed ID: 8426366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors.
    Beck-Sickinger AG; Jung G
    Biopolymers; 1995; 37(2):123-42. PubMed ID: 7893945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.
    Reymond MT; Delmas L; Koerber SC; Brown MR; Rivier JE
    J Med Chem; 1992 Oct; 35(20):3653-9. PubMed ID: 1433176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bioactive conformation of neuropeptide Y analogues at the human Y2-receptor.
    Rist B; Ingenhoven N; Scapozza L; Schnorrenberg G; Gaida W; Wieland HA; Beck-Sickinger AG
    Eur J Biochem; 1997 Aug; 247(3):1019-28. PubMed ID: 9288927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
    Cabrele C; Beck-Sickinger AG
    J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of centrally truncated analogues of neuropeptide Y at Y1 and Y2 receptor subtypes in vivo.
    McCloskey MJ; Moriarty MJ; Tseng A; Shine J; Potter EK
    Neuropeptides; 1997 Apr; 31(2):193-7. PubMed ID: 9179873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
    Kirby DA; Boublik JH; Rivier JE
    J Med Chem; 1993 Nov; 36(24):3802-8. PubMed ID: 8254609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices.
    King PJ; Widdowson PS; Doods HN; Williams G
    J Neurochem; 1999 Aug; 73(2):641-6. PubMed ID: 10428060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of high-potency neuropeptide Y analogues through systematic lactamization.
    Kirby DA; Britton KT; Aubert ML; Rivier JE
    J Med Chem; 1997 Jan; 40(2):210-5. PubMed ID: 9003519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solution structure of neuropeptide tyrosine 13-36, a Y2 receptor agonist, as determined by NMR.
    Labelle M; St-Pierre S; Savard R; Boulanger Y
    Eur J Biochem; 1997 Jun; 246(3):780-5. PubMed ID: 9219539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel cyclic analog of neuropeptide Y specific for the Y2 receptor.
    Beck-Sickinger AG; Grouzmann E; Hoffmann E; Gaida W; van Meir EG; Waeber B; Jung G
    Eur J Biochem; 1992 Jun; 206(3):957-64. PubMed ID: 1318842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sympathetic and parasympathetic interaction in vascular and secretory control of the nasal mucosa in anaesthetized dogs.
    Revington M; Lacroix JS; Potter EK
    J Physiol; 1997 Dec; 505 ( Pt 3)(Pt 3):823-31. PubMed ID: 9457655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection.
    Bader R; Bettio A; Beck-Sickinger AG; Zerbe O
    J Mol Biol; 2001 Jan; 305(2):307-29. PubMed ID: 11124908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Leu31, Pro34] NPY, a selective functional postjunctional agonist at neuropeptide-Y receptors in anaesthetised rats.
    Potter EK; McCloskey MJ
    Neurosci Lett; 1992 Jan; 134(2):183-6. PubMed ID: 1317023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-affinity relationships of C-terminal cyclic analogue of neuropeptide Y for the Y1-receptor.
    Takebayashi Y; Koga H; Togami J; Kurihara H; Furuya T; Tanaka A; Murase K
    Chem Pharm Bull (Tokyo); 2000 Dec; 48(12):1925-9. PubMed ID: 11145146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.